Tiotropium
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Tiotropium: From Chronic Obstructive Pulmonary Disease to Obstructive Lung Disease
One-Sentence Summary
Tiotropium is a long-acting muscarinic antagonist (LAMA) bronchodilator, with published literature in this Evidence Pack establishing its long-standing use as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may be effective for Obstructive Lung Disease, with 34 clinical trials and 20 publications currently supporting this direction — though reviewers should note this predicted indication overlaps substantially with tiotropium’s already-established clinical role (see “Why is This Prediction Reasonable?” below).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in structured licensing data (data gap); literature in this Evidence Pack consistently identifies COPD maintenance bronchodilation as the drug’s established use |
| Predicted New Indication | Obstructive Lung Disease |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| UK Market Status | Not marketed (per current dataset) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. Based on the accompanying clinical trial and literature evidence, tiotropium is a long-acting muscarinic (M1/M3) receptor antagonist — it dissociates slowly from M3 receptors on airway smooth muscle, producing sustained bronchodilation with once-daily dosing. This anticholinergic mechanism is the pharmacological basis for its use across the spectrum of obstructive airway conditions.
“Obstructive lung disease” is a broad diagnostic category that encompasses COPD, and the mechanistic rationale is therefore strong: LAMA-mediated bronchodilation is a first-line, guideline-endorsed approach for airflow obstruction of this type. The very large and mature trial base (including landmark studies such as the SAFE trial, NCT00277264, and the UPLIFT-type long-term lung function trial, NCT00144339) reflects decades of accumulated evidence for tiotropium’s bronchodilator effect in obstructive airway disease.
Important caveat for reviewers: the original_indications field in this Evidence Pack is empty, and a related lower-ranked candidate in the same prediction set (rank 5, “chronic obstructive pulmonary disease”) is essentially synonymous with tiotropium’s well-known existing licensed use. This suggests the TxGNN model may be flagging an already-established indication rather than a genuinely novel repurposing opportunity, most likely because the source knowledge graph lacked a populated original-indication record for this drug. This should be clarified with the regulatory data source (see Conclusion) before this candidate is treated as a discovery signal rather than a confirmatory one.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00144339 | Phase 3 | Completed | 5,993 | Large long-term trial assessing whether daily tiotropium reduces the rate of lung function decline in COPD |
| NCT01911364 | Phase 3 | Completed | 3,686 | 52-week trial comparing triple therapy (ICS/LABA/LAMA) with tiotropium alone in severe COPD |
| NCT02173769 | N/A | Completed | 1,845 | AKTIV study — real-world change in physical functioning with tiotropium/olodaterol combination therapy |
| NCT00277264 | Phase 3 | Completed | 914 | SAFE trial: one-year effect of tiotropium 18 mcg once daily on trough FEV1 versus placebo |
| NCT01316913 | Phase 3 | Completed | 872 | 24-week head-to-head comparison of umeclidinium/vilanterol with tiotropium in COPD |
| NCT00274014 | Phase 3 | Completed | 1,000 | One-year trial evaluating effect of tiotropium on severity and incidence of COPD exacerbations |
| NCT03474081 | Phase 4 | Completed | 800 | 12-week comparison of triple therapy (FF/UMEC/VI) versus tiotropium monotherapy on lung function and symptoms |
| NCT00776984 | Phase 3 | Completed | 453 | 48-week add-on trial of tiotropium in severe persistent asthma (graded A: standard efficacy design) |
| NCT00523991 | Phase 4 | Completed | 457 | 24-week efficacy/safety trial in maintenance-naïve COPD patients (graded A) |
| NCT01112241 | Phase 4 | Completed | 17 | Bronchodilator responsiveness in obliterative bronchiolitis post-haematopoietic stem cell transplant (graded B: obstructive lung disease subtype) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28877027 | 2017 | RCT | N Engl J Med | Long-term tiotropium improves lung function and slows decline in mild-to-moderate COPD |
| 25046211 | 2014 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Comprehensive review of tiotropium versus placebo across COPD trials |
| 26391969 | 2015 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Comparison of tiotropium versus ipratropium bromide in stable COPD |
| 22562275 | 2012 | Cohort | Pneumonol Alergol Pol | Effects of formoterol, formoterol+tiotropium and tiotropium alone on lung function and exercise tolerance in COPD |
| 10069510 | 1999 | Review | Life Sciences | Mechanistic and clinical profile of tiotropium (Spiriva) as an antimuscarinic bronchodilator |
| 32727455 | 2020 | Review | Respiratory Research | Review of tiotropium’s clinical development programme in COPD |
| 33095662 | 2021 | Review | Curr Med Res Opin | Evidence review for tiotropium+olodaterol fixed-dose combination in reducing COPD exacerbations |
| 29206658 | 2018 | Review | Curr Opin Pulm Med | Review of lung function trajectories in COPD and pharmacologic intervention points |
| 12010082 | 2002 | Review | Drugs | Pharmacological and clinical review of tiotropium bromide as an anticholinergic bronchodilator |
| 35510163 | 2022 | Cohort | Int J Chron Obstruct Pulmon Dis | Multicentre real-world cohort comparing tiotropium/olodaterol with other LABA/LAMA combinations in COPD |
UK Market Information
No marketing authorisation records are currently held for this drug in the Evidence Pack (total_licenses = 0, market status recorded as “Not marketed”). Given that tiotropium is a long-established respiratory bronchodilator, this is most likely a gap in the underlying regulatory data feed rather than a true absence from the UK market, and should be verified directly against the MHRA product database and current BNF listing before being used in any decision-making.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic and clinical trial evidence base for tiotropium in obstructive lung disease is extensive and mature (L1, multiple completed Phase 3 RCTs including large long-term outcome trials), giving high confidence in the pharmacological premise. However, two data gaps prevent unqualified progression: safety/warning data from the marketed product labelling is missing (flagged as Blocking in the source dataset), and the mechanism-of-action record itself is unpopulated, both of which are needed for a formal safety pre-screen.
To proceed, the following is needed:
- MHRA-sourced Summary of Product Characteristics (SmPC), including warnings, precautions and contraindications, to complete the safety pre-screen
- Confirmation of current UK marketing authorisation status (the “Not marketed” flag appears inconsistent with tiotropium’s known long-standing licensed use and should be reconciled with MHRA records)
- Clarification of whether “obstructive lung disease” represents a genuinely distinct target population from tiotropium’s existing licensed COPD indication, since the two largely overlap in this dataset
- Structured original-indication and MOA data to enable a complete mechanistic-similarity assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.